Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B…

By S. Whitman, K. Archer, Lan Feng, C. Baldus, B. Becknell, B. Carlson, A. Carroll, K. Mrózek, J. Vardiman, S. George and 4 more. Cancer Research, 2001

686 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/8a2c639f617c46261a83379e702765b38ae11d86

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. B. Cheson
2. J. Byrd
3. P. Greenberg
4. J. Bennett
5. K. Mrózek
6. P. Wijermans
7. A. Pinto
8. S. Nimer

Citations in the corpus

• Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. (2002, unknown): “CD34 cells (%) 30 (0-98) 20‡ (0-96) 22 (0-91) 10 (3-73)”
• Report of an international working group to standardize response criteria for myelodysplastic syndromes. (2000, background): “MDS will exclude cases of low-blast-count leukemias that show one of the following AML type cytogenetic abnormalities: t(8;21), inv(16), or t(15;17).”
• Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). (2006, unknown): “Median platelet count, 109/L (range) 68 (7-302)* 56 (3-514) 47 (5-372) 46 (4-1430)”
• Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). (2002, background): “06) 59 (48-69) Complex with at least 3 abnormalities 8 88 1.”